These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 31570423)

  • 1. Triple-Negative Breast Cancer: The Progress of Targeted Therapies and Future Tendencies.
    Damaskos C; Garmpi A; Nikolettos K; Vavourakis M; Diamantis E; Patsouras A; Farmaki P; Nonni A; Dimitroulis D; Mantas D; Antoniou EA; Nikolettos N; Kontzoglou K; Garmpis N
    Anticancer Res; 2019 Oct; 39(10):5285-5296. PubMed ID: 31570423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple-negative breast cancer molecular subtyping and treatment progress.
    Yin L; Duan JJ; Bian XW; Yu SC
    Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
    Williams CB; Soloff AC; Ethier SP; Yeh ES
    Adv Cancer Res; 2015; 127():253-81. PubMed ID: 26093903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple negative breast cancer: special histological types and emerging therapeutic methods.
    Cao L; Niu Y
    Cancer Biol Med; 2020 May; 17(2):293-306. PubMed ID: 32587770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
    Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
    Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.
    Agelaki S; Dragolia M; Markonanolaki H; Alkahtani S; Stournaras C; Georgoulias V; Kallergi G
    Oncotarget; 2017 Jan; 8(3):5309-5322. PubMed ID: 28029660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in Targeted Therapies for Triple-Negative Breast Cancer.
    McCann KE; Hurvitz SA; McAndrew N
    Drugs; 2019 Jul; 79(11):1217-1230. PubMed ID: 31254268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.
    Massihnia D; Galvano A; Fanale D; Perez A; Castiglia M; Incorvaia L; Listì A; Rizzo S; Cicero G; Bazan V; Castorina S; Russo A
    Oncotarget; 2016 Sep; 7(37):60712-60722. PubMed ID: 27474173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
    Costa RLB; Han HS; Gradishar WJ
    Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promising therapeutic options in triple-negative breast cancer.
    Bilici A; Arslan C; Altundag K
    J BUON; 2012; 17(2):209-22. PubMed ID: 22740196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Progress in Triple Negative Breast Cancer Research.
    Mouh FZ; Mzibri ME; Slaoui M; Amrani M
    Asian Pac J Cancer Prev; 2016; 17(4):1595-608. PubMed ID: 27221827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials in triple negative breast cancer.
    Reeder-Hayes KE; Carey LA; Sikov WM
    Breast Dis; 2010; 32(1-2):123-36. PubMed ID: 21778571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic targets of triple-negative breast cancer: a review.
    Jamdade VS; Sethi N; Mundhe NA; Kumar P; Lahkar M; Sinha N
    Br J Pharmacol; 2015 Sep; 172(17):4228-37. PubMed ID: 26040571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
    Moy B; Rumble RB; Come SE; Davidson NE; Di Leo A; Gralow JR; Hortobagyi GN; Yee D; Smith IE; Chavez-MacGregor M; Nanda R; McArthur HL; Spring L; Reeder-Hayes KE; Ruddy KJ; Unger PS; Vinayak S; Irvin WJ; Armaghani A; Danso MA; Dickson N; Turner SS; Perkins CL; Carey LA
    J Clin Oncol; 2021 Dec; 39(35):3938-3958. PubMed ID: 34324366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecularly targeted therapies for metastatic triple-negative breast cancer.
    Bayraktar S; Glück S
    Breast Cancer Res Treat; 2013 Feb; 138(1):21-35. PubMed ID: 23358903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple-negative breast cancer: is there a treatment on the horizon?
    Yao H; He G; Yan S; Chen C; Song L; Rosol TJ; Deng X
    Oncotarget; 2017 Jan; 8(1):1913-1924. PubMed ID: 27765921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises.
    Garmpis N; Damaskos C; Garmpi A; Kalampokas E; Kalampokas T; Spartalis E; Daskalopoulou A; Valsami S; Kontos M; Nonni A; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
    Cancer Genomics Proteomics; 2017; 14(5):299-313. PubMed ID: 28870998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast Cancer: Current Molecular Therapeutic Targets and New Players.
    Nagini S
    Anticancer Agents Med Chem; 2017; 17(2):152-163. PubMed ID: 27137076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.